Economic modeling is an accepted tool for making formulary decisions by payers in the US. Hospital and institutional healthcare providers have expressed increased interest in using economic modeling in their decision making processes, particularly regarding potential reimbursement based on hospital-specific pricing. This study presents hospital perspective results from a revenue impact (RI) calculator component of an economic model. METHODS: An economic model was developed that investigated the RI (pharmaceutical acquisition costs minus projected reimbursement) of introducing National Comprehensive Cancer Network Category 1 recommended therapies for BRAF V600 mutated metastatic melanoma to a hospital formulary. Therapies investigated in the analysis included: dabrafenib+trametinib combination therapy, vemurafenib monotherapy, dabrafenib monotherapy, and trametinib monotherapy. The model calculated the annual pharmaceutical acquisition cost of each therapy based on recommended dosing, progression-free survival as a marker for duration of treatment, and drug pricing. Pricing data was retrieved from the Truven Health Analytics RED BOOK™ database. Acquisition costs in the model could be set to 340B, wholesale acquisition cost (WAC), or average wholesale price (AWP) values. The model used a default 30% discount compared to WAC to approximate 340B pricing. The projected reimbursement in the model uses WAC plus a modifiable 4.3% (based on the Medicare permitted reimbursement premium) for both Medicare and commercial payers. The perspective payer mix and respective reimbursement percentages can be modified by the model user. WAC was used in place of average sales price (ASP) due to the unavailability of hospital-specific ASP per therapy. RESULTS: Annual net reimbursement revenues per patient based on 340B acquisition costs were projected to be $53,270 for dabrafenib+trametinib combination, $27,043 for vemurafenib, $22,634 for dabrafenib, and $19,029 for trametinib. CONCLUSIONS: The addition of user-modifiable projected reimbursement revenue calculation is a valuable tool that expands the contribution of economic modeling to hospital formulary decisionmaking. • This model allows hospital specific inputs for numbers of patients using each treatment or a headto-head comparison between two treatments.
• Budget impact models developed for large health plans have not been directly applicable to institutional or hospital pharmacists.
• This model allows hospital specific inputs for numbers of patients using each treatment or a headto-head comparison between two treatments.
• The model allows user specification of reimbursement rates to project reimbursement revenue.
• Projecting reimbursement revenue is a novel feature for a BIM. 
MODELING ANNUAL PROJECTED REVENUE IMPACT OF THERAPY INTRODUCTION FOR PATIENTS WITH BRAF V600 METASTATIC MELANOMA FROM A HOSPITAL PERSPECTIVE

Treatment Options
The comparator list contains regimens recommended for metastatic melanoma patients with V600 BRAF mutations with available real world data. Costs are reported for individual years and thus are not discounted. BIM guidelines recommend against discounting. Currently the base-case treatment or administration costs include no co-medications. Table  1 shows dosing for treatments. 
Population
The hospital perspective RI calculator gives a hospital representative the ability to select the number of patients treated in a given year. The number of patients to be treated for each comparator are assumed to be the same as there is a direct one to one comparison of each comparator in the model.
In order to determine the projected reimbursement revenue, the proportion of the population that is commercial and Medicare is specified. A reimbursement rate is then specified for each of these selections. The reimbursement rate + the WAC cost are then used to project the total reimbursement.
Reimbursement Inputs
The hospital reimbursement contains the proportion commercial/Medicare as well as the reimbursement percentages. These values are modifiable in the RI calculator. Default values in Table 4 are used to estimate the projected reimbursement revenue.
Annual Costs and Reimbursement
The hospital reimbursement uses the WAC + reimbursement % to calculate the reimbursement total. Commonly used average sales price (ASP) values are not readily available. The modifiable WAC cost in the BIM is instead used to calculate the commercial and Medicare reimbursement. Base-case cost and reimbursement results are shown in Table 5 .
Reimbursement Revenue
The commercial and Medicare reimbursement totals are summed to estimate the total reimbursement for the hospital displayed in Table 6 . From this, the total reimbursement then subtracts the total treatment cost (340B Pricing) to get the projected reimbursement revenue.
Treatment Costs
The hospital population has the option to select average wholesale price (AWP), wholesale acquisition cost (WAC), or 340B pricing. The AWP and WAC prices are taken from the Truven Health Analytics RED BOOK™ database. 6 The 340B pricing is implemented as a fixed user specified discount percentage from the WAC pricing set in the model. Alternatively, if discounts are variable, 340B prices for each comparator can be specified separately. This analysis assumes a 30% discount from WAC in the model. Table 2 shows the treatment cost inputs.
The administration and infusion costs are not accounted for in the results as these costs are not included in the total reimbursement.
Cost per Month and Duration of Treatment
The RI calculator calculates the least expensive combination of tablets to distribute per dose. Dependent upon the number of cycles specified, the monthly cost is calculated to determine the treatment cost per patient per month.
Duration of treatment is assumed to be less than a year for all patients. Progression-free survival data was used as a representative value for median duration of treatment where not available. Limiting the number of cycles for duration of treatment is a common occurrence for the clinical trials that look at metastatic melanoma. The areas under exponential curves are used to convert median durations to means. Table 3 displays treatment specific inputs.
Melanoma is the fifth most common cancer in men and the seventh most common in women, with an estimated 73,870 new cases to be diagnosed in 2015. 1 Melanoma accounts for less than 2% of all skin cancers, but is responsible for most skin cancer deaths. 1 Survival rates for melanoma once it has metastasized drop significantly. 1 About half of all melanomas have a mutation of the BRAF oncogene, 2 a signaling protein along the ERK/MAP kinase signaling pathway associated with rapid melanoma cell growth. 3, 4 Several new drugs have emerged that target mutated proteins along the MAP kinase signaling pathway. 2 The National Comprehensive Cancer Network treatment guidelines for metastatic melanoma have identified dabrafenib, trametinib, combination dabrafenib+trametinib, and vemurafenib as category 1 therapy options for the treatment of metastatic melanoma in patients with BRAF V600 mutations. 5 Traditional budget impact models (BIMs) have targeted commercial and Medicare audiences where treatment, administration and any secondary costs are relevant. A hospital/institutional audience is focused primarily on drug and administration costs to help calculate prospective revenue impact (RI) for a limited number of patients. 
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